Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29155426

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Nat Med
Publication date
2018 Jan
First author
Fry TJ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Fry TJ
      type
      Author
    2. name
      Shah NN
      type
      Author
    3. name
      Orentas RJ
      type
      Author
    4. name
      Stetler-Stevenson M
      type
      Author
    5. name
      Yuan CM
      type
      Author
    6. name
      Ramakrishna S
      type
      Author
    7. name
      Wolters P
      type
      Author
    8. name
      Martin S
      type
      Author
    9. name
      Delbrook C
      type
      Author
    10. name
      Yates B
      type
      Author
    11. name
      Shalabi H
      type
      Author
    12. name
      Fountaine TJ
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Fry TJ
      type
      Author
    2. name
      Shah NN
      type
      Author
    3. name
      Orentas RJ
      type
      Author
    4. name
      Stetler-Stevenson M
      type
      Author
    5. name
      Yuan CM
      type
      Author
    6. name
      Ramakrishna S
      type
      Author
    7. name
      Wolters P
      type
      Author
    8. name
      Martin S
      type
      Author
    9. name
      Delbrook C
      type
      Author
    10. name
      Yates B
      type
      Author
    11. name
      Shalabi H
      type
      Author
    12. name
      Fountaine TJ
      type
      Author
    bibliography ids
    1. nci-bib-03f2cc6f9d71ca91b65c792b
    book metadata
    content sha256
    9590011c97703783cdb5a4f624069eb0271a164204430bf10954918db0070205
    document type
    citation
    dois
    1. 10.1038/nm.4441
    electronic publication date
    display
    2017 Nov 20
    precision
    day
    year
    2017
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:29155426
    immutable id
    pubmed:29155426@9590011c97703783cdb5a4f624069eb0271a164204430bf10954918db0070205
    journal
    abbreviation
    Nat Med
    issn electronic
    1546-170X
    issn print
    1078-8956
    issue
    1
    name
    Nature medicine
    nlm unique id
    9502015
    pages
    20-28
    volume
    24
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      29155426
      provenance
      batch id
      fb25b16edcb1373b70c1
      provider
      NCBI PubMed ESummary
      record sha256
      6673215a755d2b3d33a7f2c8cdb6ef1930f0a1e10bb361aa3ab72021f0da7944
      response sha256
      182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
      retrieved at
      2026-09-09T23:47:28.490065+00:00
      publication date
      display
      2018 Jan
      precision
      month
      year
      2018
      publication types
      1. Clinical Trial, Phase I
      2. Journal Article
      3. Research Support, N.I.H., Intramural
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/29155426/
      title
      CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

      Preserved source evidence · Not medical advice